Population analysis of the pharmacokinetics and pharmacodynamics of RWJ270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers

AAPS Journal

Volumn 4, Issue 4, 2002, Pages

  Lyer, Ganesh R ^a,b   Liao, Sam ^a,c   Massarella, Joseph ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c PharmMax Research   (United States)

Author keywords

Influenza virus; Pharmacokinetics and pharmacodynamics; Population; RWJ 270201

Indexed keywords

EID: 52449105527     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. The Lancet. 2000;355:827-835.
2. Calfee DP, Hayden FG. New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs. 1998;56:537-553.
3. Kirn CU, Chen X, Mendel DB. Neuraminidase inhibitors as anti influenza virus agents. Antiviral Chem Chemother. 1999;10:141-154.
4. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker; 1982:31-56.
5. Holford NHG, Sheiner LB. Understanding the dose-effect relationship. Clinical applications of pharmacokineticpharmacodynamic models. Clin Pharmacokinet. 1981;6:429-453.
6. WinNonMix User's Guide. Pharsight Corp. Version 2.0; 2000.
7. Ette El, Ludden TM. Population pharmaokinetic model building: The use of informative graphics. Pharm Res. 1995;12:1845-1855.
8. Food and Drug Administration. FDA Guidance for Industry: Population Pharmacokinetics. Rockville, MD: National Press Office; February 1999.
9. Ette El. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.
10. Drusano GL. Pharmacodynamics of antiretroviral chemotherapy. Infec Control Hosp Epidemiol. 1993;14:530-536.
11. Weller S, Radomski KM, Lou Y, Stein DS. Population Pharmacokinetics and pharmacodynamic modeling of Abacavir from a dose ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemothera. 2000;44:2052-2060.
12. Smith PF, Puchalski TT, Forrest A. Optimal design of Phase II antiretoviral, short-term monotherapy clinical trials. Poster # 1653. Presented at: ICAAC Meeting; September 2000; Toronto, Canada.